A case of kidney injury induced by capecitabine tablets

Published on Feb. 15, 2023Total Views: 1598 times Total Downloads: 690 times Download Mobile

Author: Juan PAN ¹ Xian-Bin WANG ² Ling-Zhi ZHOU ¹  Zu-Yi LI ¹

Affiliation: 1. Department of Pharmacy, Liuyang Hospital of Traditional Chinese Medicine, Liuyang 410300, Hunan Province, China 2. Department of Anorectal Breast, Liuyang Hospital of Traditional Chinese Medicine, Liuyang 410300, Hunan Province, China

Keywords: Capecitabine Kidney injury Adverse drug reaction Case report

DOI: 10.19960/j.issn.1005-0698.202302016

Reference: Juan PAN, Xian-Bin WANG, Ling-Zhi ZHOU, Zu-Yi LI.A case of kidney injury induced by capecitabine tablets[J].Yaowu Liuxingbingxue Zazhi,2023, 32(2): 237-240.DOI: 10.19960/j.issn.1005-0698.202302016.[Article in Chinese]  Copied

Abstract
Full-text
References

Abstract

A 72-year-old male patient with rectal cancer received single-agent chemotherapy with capecitabine tablets (the dosage regimen was 1.5 g in the morning and 1.75 g in the evening, 2 week medication followed by 1 week discontinuation, 3 weeks was a cycle). On the second day after discontinuation of the third cycle of capecitabine, oliguria began and retching developed five days later. Laboratory tests showed serum creatinine 226 μmol·L^-1, urea 14.40 mmol·L^-1, and uric acid 601 μmol·L^-1. The diagnosis of kidney injury was considered to be related to capecitabine tablets. Symptomatic treatment such as rehydration and kidney protection were given. Four days later, the symptoms above-mentioned in the patient were improved obviously, and on the 7th day after admission, his renal function index basically returned to normal.

Full-text

Please download the PDF version to read the full text: download

References

1. National Cancer Institute, National Institutes of Health. US Department of Health and Human Services: Common Terminology Criteria for Adverse Events (CTCAE)[EB/OL].(2017-11-27) [2022-11-10]. https://evs.nci.nih.gov/ftp1/CTCAE/About.html.

2. Kellum JA, Lameire N, Aspelin P, et al. Kidney disease: Improving global outcomes (KDIGO) acute kidney injury work group. KDIGO clinical practice guideline for acute kidney injury[J]. Kidney Int Suppl, 2012, 2(1): 1-138. DOI: 10.1038/kisup.2012.1.

3. 国家食品药品监督管理局药品安全监管司, 国家药品不良反应监测中心.药品不良反应报告和监测工作手册[EB/OL]. (2011-05-04) [2022-11-10]. https://gkml.samr.gov.cn/nsjg/bgt/202106/t20210629_331741.html.

4. Mizio GD, Gallelli L, Barbieri V, et al. Capecitabine-induced, rapid decrease of renal function due to drug dispensing error in a hospital pharmacy[J]. J Clin Pharmacol, 2011, 51(1): 117-119. DOI: 10.1177/009127 0010365552.

5. Arroyo YM, Narasimha S, Bertran-Rodriguez CE, et al. Case of capecitabine-induced diarrhea leading to renal failure requiring hemodialysis[J]. Am J Gastroenterol, 2019, 114(Supplement): S1677. DOI: 10.14309101.ajg.0000602004.96949.e8.

6. Naranjo CA, Shear NH, Lanctôt KL. Advance in the diagnosis of adverse drug reactions[J]. J Clin Pharmacol, 1992, 32(10): 897-904. DOI: 10.1002/j.1552-4604.1992.tb04635.x.

7. 刘云海, 王虹, 吕正松. 抗肿瘤前体药物——卡培他滨[J]. 医药导报, 2004, 23(3): 201-203. [Liu YH, Wang H, Lyu ZS. Capecitabine, an antineoplastic precursor drug[J]. Herald of Medicine, 2004, 23(3): 201-203.] DOI: 10.3870/j.issn.1004-0781.2004.03.038

8. 陈佳, 陈力, 普燕芳, 等. 基于FAERS数据库的氟尿嘧啶和卡培他滨不良事件信号挖掘研究[J]. 肿瘤药学, 2022, 12(5): 632-639. [Chen J, Chen L, Pu YF, et al. Research on signal mining of fluorouracil and capecitabine adverse events based on FAERS database[J]. Anti-Tumor Pharmacy, 2022, 12(5): 632-639.] DOI: 10.3969/j.issn.2095-1264.2022.05.12.

9. Park JY. Analysis of data on capecitabine-related adverse drug reactions from the Korean adverse event reporting system database[J]. Eur J Oncol Nurs, 2018, 34: 55-60. DOI: 10.1016/j.ejon.2018.03.004.

10.Mosseri M, Fingert H, Varticovski L, et al. In vitro evidence that myocardial ischemia resulting from 5-fluorouracil chemotherapy is due to protein kinase C-mediated vasoconstriction of vascular smooth muscle[J]. Cancer Res, 1993, 53(13): 3028-3033. https://pubmed.ncbi.nlm.nih.gov/8391384/.